Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasting During Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer
NCT06386887Recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jul 2024
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoints: Intermittent fasting compliance as measured by serum glucose laboratory testing at Week 6, Intermittent fasting compliance as measured by ketone laboratory testing at Week 6 and 5 more. Started Jul 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06386887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06386887.